Dr.ObesityLA said:Extending the interval and reducing the dose are pharmacologically different.
The regain framing needs pushing back on. Two thirds regained means one third did not, and the trial provided no ongoing support to either group. Treating regain as pharmacologically inevitable is as unsupported as treating maintenance as automatic.
Worth separating that from lean-mass preservation, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.